1 hasil untuk "Jane Scott"

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)

Tarik Asselah; Christophe Moreno; Christoph Sarrazin dkk.

PLOS ONE, Vol. 11 No. 7 · 2016 · Inggris · PLOS Scopus

Background: Shortening duration of peginterferon-based HCV treatment reduces associated burden for patients. Primary objectives of this study were to assess the efficacy against the minimally acceptable response rate 12 weeks post-treatment (SVR12) and safety of simeprevir plus PR in…